{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5%25+human+albumin&page=2", "query": { "intervention": "5% human albumin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 76, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5%25+human+albumin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5%25+human+albumin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T20:51:34.995Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03554109", "title": "QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "haNK", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin HCL", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-09", "completion_date": "2022-02-09", "has_results": false, "last_update_posted_date": "2025-02-21", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554109" }, { "nct_id": "NCT06998940", "title": "Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Irinotecan Sucrosofate", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2026-05-13", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 274, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06998940" }, { "nct_id": "NCT03378102", "title": "Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Allogeneic Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "IFN-gamma-secreting HAdV antigen specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mari Dallas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": null, "sex": "ALL", "summary": "3 Months and older" }, "enrollment_count": 20, "start_date": "2019-01-04", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03378102" }, { "nct_id": "NCT07408583", "title": "Prenatal Transplantation for Fetuses With Fanconi Anemia", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fanconi Anemia", "Anemia, Hypoplastic, Congenital", "Congenital Bone Marrow Failure Syndromes", "Bone Marrow Failure Disorders", "Genetic Diseases, Inborn", "Congenital, Hereditary, and Neonatal Diseases and Abnormalities", "DNA Repair-Deficiency Disorders", "Cancer Predisposition Syndrome" ], "interventions": [ { "name": "IUHSCT for FA-affected fetuses", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Agnieszka Czechowicz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2028-01", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 2, "location_summary": "San Francisco, California • Stanford, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07408583" }, { "nct_id": "NCT00220740", "title": "Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" ], "interventions": [ { "name": "Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified", "type": "DRUG" }, { "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2004-04", "completion_date": "2006-06", "has_results": true, "last_update_posted_date": "2016-03-23", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 6, "location_summary": "New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220740" }, { "nct_id": "NCT02654782", "title": "Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemodynamic Stability" ], "interventions": [ { "name": "Lactated Ringer's", "type": "DRUG" }, { "name": "5% Human Albumin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "William C. Oliver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2016-01", "completion_date": "2017-10-09", "has_results": true, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02654782" }, { "nct_id": "NCT02882074", "title": "Endothelial Function After Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endothelial Dysfunction" ], "interventions": [ { "name": "Human albumin", "type": "DRUG" }, { "name": "Hydroxyethyl starch", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 85, "start_date": "2016-06", "completion_date": "2020-02-20", "has_results": true, "last_update_posted_date": "2024-02-01", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02882074" }, { "nct_id": "NCT02872142", "title": "Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "Albutein 5%", "type": "BIOLOGICAL" }, { "name": "Plasma Exchange", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "19 Years to 69 Years" }, "enrollment_count": 12, "start_date": "2016-08-29", "completion_date": "2019-08-15", "has_results": true, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02872142" }, { "nct_id": "NCT06534450", "title": "The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Aging" ], "interventions": [ { "name": "Sham", "type": "DEVICE" }, { "name": "Therapeutic Plasma Exchange", "type": "DEVICE" }, { "name": "IVIG", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Dobri Kiprov", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "50 Years to 95 Years" }, "enrollment_count": 40, "start_date": "2022-09-12", "completion_date": "2025-08", "has_results": false, "last_update_posted_date": "2024-08-02", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 1, "location_summary": "Mill Valley, California", "locations": [ { "city": "Mill Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06534450" }, { "nct_id": "NCT07705919", "title": "DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gadolinium-Chelate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Point-of-care portable perfusion phantom (P4)", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-10-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-08T20:51:34.995Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07705919" } ] }